Compare FORA & XBIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FORA | XBIT |
|---|---|---|
| Founded | 2014 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Pharmaceuticals and Biotechnology |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 67.3M | 75.0M |
| IPO Year | 2020 | 2015 |
| Metric | FORA | XBIT |
|---|---|---|
| Price | $2.16 | $2.49 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 39.5K | 22.3K |
| Earning Date | 05-13-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 25.00 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $30,256,919.00 | N/A |
| Revenue This Year | $8.44 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 50.13 | N/A |
| 52 Week Low | $1.64 | $2.09 |
| 52 Week High | $2.71 | $3.61 |
| Indicator | FORA | XBIT |
|---|---|---|
| Relative Strength Index (RSI) | 60.16 | 51.65 |
| Support Level | $2.11 | $2.15 |
| Resistance Level | $2.20 | $2.69 |
| Average True Range (ATR) | 0.01 | 0.08 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 33.33 | 33.05 |
Forian Inc provides a suite of Software, data management capabilities, and proprietary data and analytics to optimize and measure operational, clinical, and financial performance for customers within the traditional and emerging life sciences, healthcare payer, and provider segments, as well as cannabis dispensaries, manufacturers, and cultivators.
XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.